677.1K XNYS Volume
XNYS 19 Mar, 2025 12:11 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Philippe Sauvage | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Colleen Sjogren | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Moses Makunje | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Dongfang Liu | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| David C. Hanley | CHIEF TECHNICAL OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Stacy Markel | CHIEF PEOPLE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Gary Hattersley | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| David T. Hung | Director, PRESIDENT AND CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 2,000,000 | 2,000,000 | - | - | Stock Option (Right to Buy) | |
| Kerry Wentworth | CHIEF REGULATORY OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2025 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 11 Nov 2024 | 56,361 | 3,866,228 | - | 2.9 | 162,883 | Class A Common Stock | |
| Robert Mashal | Director | Purchase of securities on an exchange or from another person at price $ 2.21 per share. | 08 Oct 2024 | 19 | 19 | - | 2.2 | 42 | Class A Common Stock |
| Robert Mashal | Director | Purchase of securities on an exchange or from another person at price $ 2.20 per share. | 08 Oct 2024 | 99,981 | 100,000 | - | 2.2 | 219,958 | Class A Common Stock |
| Philippe Sauvage | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2024 | 750,000 | 750,000 | - | - | Stock Option (Right to Buy) | |
| Xiangmin Cui | Director | 03 Sep 2024 | 128,792 | 0 | - | - | Series A Preferred Stock | ||
| Xiangmin Cui | Director | 03 Sep 2024 | 5,157,900 | 7,611,031 | - | - | Class A Common Stock | ||
| Xiangmin Cui | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 437,834 | 437,834 | - | - | Warrants (Right to Buy) | |
| Xiangmin Cui | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 175,346 | 175,346 | - | - | Warrants (Right to Buy) | |
| Xiangmin Cui | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 32,877 | 32,877 | - | - | Warrants (Right to Buy) | |
| Xiangmin Cui | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 128,792 | 128,792 | - | - | Series A Preferred Stock | |
| Xiangmin Cui | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 51,579 | 51,579 | - | - | Series A Preferred Stock | |
| Xiangmin Cui | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 9,671 | 9,671 | - | - | Series A Preferred Stock | |
| Xiangmin Cui | Director | 03 Sep 2024 | 12,879,200 | 17,062,202 | - | - | Class A Common Stock | ||
| Xiangmin Cui | Director | 03 Sep 2024 | 967,100 | 1,281,206 | - | - | Class A Common Stock | ||
| Xiangmin Cui | Director | 03 Sep 2024 | 51,579 | 0 | - | - | Series A Preferred Stock | ||
| Xiangmin Cui | Director | 03 Sep 2024 | 9,671 | 0 | - | - | Series A Preferred Stock | ||
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 03 Sep 2024 | 25,436 | 0 | - | - | Series A Preferred Stock | ||
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 03 Sep 2024 | 57,647 | 57,647 | - | - | Warrants (Right to Buy) | ||
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 03 Sep 2024 | 16,957 | 0 | - | - | Series A Preferred Stock | ||
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 03 Sep 2024 | 86,471 | 86,471 | - | - | Warrants (Right to Buy) | ||
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 03 Sep 2024 | 16,957 | 16,957 | - | - | Series A Preferred Stock | ||
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 03 Sep 2024 | 25,436 | 25,436 | - | - | Series A Preferred Stock | ||
| Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 200,801 | 200,801 | - | - | Stock Option (Right to Buy) | |
| W. Anthony Vernon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 200,801 | 200,801 | - | - | Stock Option (Right to Buy) | |
| Kim D. Blickenstaff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 200,801 | 200,801 | - | - | Stock Option (Right to Buy) | |
| Kathryn E. Falberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 200,801 | 200,801 | - | - | Stock Option (Right to Buy) | |
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 03 Sep 2024 | 2,543,600 | 3,922,589 | - | - | Class A Common Stock | ||
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 03 Sep 2024 | 1,695,700 | 2,246,458 | - | - | Class A Common Stock | ||
| Xiangmin Cui | Director | Purchase of securities on an exchange or from another person at price $ 2.97 per share. | 25 Jun 2024 | 277,895 | 2,453,131 | - | 3.0 | 825,348 | Class A Common Stock |
| Xiangmin Cui | Director | Purchase of securities on an exchange or from another person at price $ 2.99 per share. | 20 Jun 2024 | 87,715 | 1,762,951 | - | 3.0 | 262,268 | Class A Common Stock |
| Xiangmin Cui | Director | Purchase of securities on an exchange or from another person at price $ 3.00 per share. | 20 Jun 2024 | 75,411 | 1,838,362 | - | 3 | 226,233 | Class A Common Stock |
| Xiangmin Cui | Director | Purchase of securities on an exchange or from another person at price $ 2.98 per share. | 20 Jun 2024 | 336,874 | 2,175,236 | - | 3.0 | 1,003,885 | Class A Common Stock |
| Kim D. Blickenstaff | Director | Purchase of securities on an exchange or from another person at price $ 2.90 per share. | 11 Jun 2024 | 172,189 | 172,189 | - | 2.9 | 500,089 | Class A Common Stock |
| Daniel G. Welch | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. | 24 May 2024 | 366,744 | 659,947 | - | 1.6 | 601,460 | Class A Common Stock |
| Daniel G. Welch | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2024 | 366,744 | 0 | - | - | Stock Option (Right to Buy) | |
| Daniel G. Welch | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2024 | 293,203 | 19,547 | - | - | Stock Option (Right to Buy) | |
| Daniel G. Welch | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.74 per share. | 24 May 2024 | 293,203 | 293,203 | - | 1.7 | 510,173 | Class A Common Stock |
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 09 Apr 2024 | 550,758 | 550,758 | - | 0 | Class A Common Stock | ||
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 09 Apr 2024 | 1,378,989 | 1,378,989 | - | 0 | Class A Common Stock | ||
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 09 Apr 2024 | 388,299 | 388,299 | - | - | Stock Option (Right to Buy) | ||
| Junyuan Wang | Director, CEO, ANHEART THERAPEUTICS LTD. | 09 Apr 2024 | 486,669 | 486,669 | - | - | Stock Option (Right to Buy) | ||
| Colleen Sjogren | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2024 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Colleen Sjogren | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2024 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Xiangmin Cui | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2024 | 314,106 | 314,106 | - | - | Class A Common Stock | |
| Xiangmin Cui | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2024 | 4,183,002 | 4,183,002 | - | - | Class A Common Stock | |
| Xiangmin Cui | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Apr 2024 | 1,675,236 | 1,675,236 | - | - | Class A Common Stock | |
| Moses Makunje | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 250,000 | 250,000 | - | - | Class A Common Stock | |
| Dongfang Liu | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| David C. Hanley | CHIEF TECHNICAL OPERATIONS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Stacy Markel | CHIEF PEOPLE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Gary Hattersley | CHIEF SCIENTIFIC OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| David T. Hung | Director, PRESIDENT AND CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 2,000,000 | 2,000,000 | - | - | Stock Option (Right to Buy) | |
| Kerry Wentworth | CHIEF REGULATORY OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Robert Mashal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2024 | 741,179 | 741,179 | - | - | Stock Option (Right to Buy) | |
| Oleg Nodelman | Director | Purchase of securities on an exchange or from another person at price $ 1.36 per share. | 19 Sep 2023 | 117,100 | 12,621,775 | - | 1.4 | 159,490 | Class A Common Stock |
| Oleg Nodelman | Director | Purchase of securities on an exchange or from another person at price $ 1.36 per share. | 19 Sep 2023 | 53,000 | 12,674,775 | - | 1.4 | 72,138 | Class A Common Stock |
| Oleg Nodelman | Director | Purchase of securities on an exchange or from another person at price $ 1.26 per share. | 19 Sep 2023 | 5,143,000 | 12,504,675 | - | 1.3 | 6,460,637 | Class A Common Stock |
| Daniel G. Welch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 366,744 | 366,744 | - | - | Stock Option (Right to Buy) | |
| Kathryn E. Falberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 366,744 | 366,744 | - | - | Stock Option (Right to Buy) | |
| Kim D. Blickenstaff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 366,744 | 366,744 | - | - | Stock Option (Right to Buy) | |
| W. Anthony Vernon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 366,744 | 366,744 | - | - | Stock Option (Right to Buy) | |
| Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 366,744 | 366,744 | - | - | Stock Option (Right to Buy) | |
| Kerry Wentworth | Chief Regulatory Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Stacy Markel | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer A. Fox | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
| David C. Hanley | Chief Technical Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Dongfang Liu | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Gary Hattersley | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Kathryn E. Falberg | Director | Purchase of securities on an exchange or from another person at price $ 1.95 per share. | 30 Nov 2022 | 43,000 | 250,000 | - | 2.0 | 83,962 | Class A Common Stock |
| Kathryn E. Falberg | Director | Purchase of securities on an exchange or from another person at price $ 1.98 per share. | 30 Nov 2022 | 47,000 | 207,000 | - | 2.0 | 93,187 | Class A Common Stock |
| Kathryn E. Falberg | Director | Purchase of securities on an exchange or from another person at price $ 1.97 per share. | 30 Nov 2022 | 84,959 | 160,000 | - | 2.0 | 167,599 | Class A Common Stock |
| Kathryn E. Falberg | Director | Purchase of securities on an exchange or from another person at price $ 1.85 per share. | 30 Nov 2022 | 75,041 | 75,041 | - | 1.9 | 139,088 | Class A Common Stock |
| Jennifer A. Fox | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2022 | 480,000 | 480,000 | - | - | Stock Option (Right to Buy) | |
| Dongfang Liu | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Aug 2022 | 315,000 | 315,000 | - | - | Stock Option (Right to Buy) | |
| Dongfang Liu | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 490,000 | 490,000 | - | - | Stock Option (Right to Buy) | |
| Dongfang Liu | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2022 | 292,500 | 292,500 | - | - | Stock Option (Right to Buy) | |
| Daniel G. Welch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 140,713 | 140,713 | - | - | Stock Option (Right to Buy) | |
| Kathryn E. Falberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 140,713 | 140,713 | - | - | Stock Option (Right to Buy) | |
| Kim D. Blickenstaff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 140,713 | 140,713 | - | - | Stock Option (Right to Buy) | |
| W. Anthony Vernon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 140,713 | 140,713 | - | - | Stock Option (Right to Buy) | |
| Robert B. Bazemore | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 140,713 | 140,713 | - | - | Stock Option (Right to Buy) | |
| David T. Hung | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 2,000,000 | 2,000,000 | - | - | Stock Option (Right to Buy) | |
| Jennifer A. Fox | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 600,000 | 600,000 | - | - | Stock Option (Right to Buy) | |
| David T. Hung | Director, President and CEO, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 02 Mar 2021 | 368,408 | 58,281,054 | - | 0 | Class A Common Stock | |
| David T. Hung | Director, President and CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 2,500,000 | 2,500,000 | - | - | Stock Option (Right to Buy) |